Study of KL1333 for adult mitochondrial disease fatigue and weakness
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This Phase 2 trial studies whether KL1333 improves chronic fatigue and muscle weakness in adults with a confirmed mitochondrial genetic disease. You may be eligible if you have persistent fatigue for at least 3 months and signs of muscle involvement, and can safely follow study requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older with a confirmed mitochondrial disease linked to a known gene or mtDNA deletion
- Your mitochondrial disease affects multiple body systems (not mainly brain/nerve degeneration conditions like Leigh or LHON)
- You’ve had mitochondrial fatigue for at least 3 months and your fatigue score is at a moderate level or higher
- You have signs of muscle involvement or limited exercise tolerance on the study’s strength/mobility checks
- You can safely do the 30-second sit-to-stand test within the allowed repetition range, and you’re generally medically stable
- You can follow key medication and lifestyle rules, including stable diet and holding certain supplements; and certain pregnancy protections if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This natural history study follows children and adults with suspected or confirmed mitochondrial myopathy to better understand symptoms and how the condition changes. It may also include healthy participants to compare test results and improve future treatments.
This trial tests a new medicine, sonlicromanol, for people with a specific type of mitochondrial disease (caused by the m.3243A>G mutation) who also have chronic fatigue and muscle weakness. The goal is to see if it helps improve symptoms and daily function.
This is a follow-up study for patients who completed a previous trial (FALCON) testing KL1333, an experimental medicine for primary mitochondrial disease—a condition where cells don't produce enough energy. The study tracks how safe and effective the treatment remains over time.
This study observes people with primary mitochondrial muscle diseases over time to better understand how symptoms change. It may help improve future care by learning patterns of muscle weakness, fatigue, and related complications.
This study looks at how metabolism, infections, and the immune system work together in people with mitochondrial disease. It aims to learn more about the condition and may help guide future treatments.
This Phase 1 study tests a special MRI approach (using a contrast agent) to better measure changes in muscles in people with mitochondrial diseases. It also includes some healthy volunteers and other critically ill patients to compare results and check safety.
Hear when a new Primary Mitochondrial Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.